JAFRON(SZ:300529)2024-09-12 13:38Group 1: Internationalization and Market Penetration - The company's products are currently used in over 2,000 hospitals worldwide, with more than 90 types of HA series blood perfusion devices and BS series bilirubin adsorption devices having obtained EU MDR certification, facilitating promotion and sales in EU countries and other regions recognizing this certification [2] - In the liver disease sector, the company has covered over 2,000 hospitals, while products related to critical care have reached over 1,600 hospitals [3] - The penetration rate of blood perfusion technology in the liver and critical care fields is still in the early stages, indicating significant growth potential [3] Group 2: Product Development and Future Prospects - The pHA series blood perfusion devices, launched in November 2023, are the first globally to effectively adsorb both large molecular toxins and protein-bound toxins in uremic patients, with over 60 hospitals currently promoting their use [3] - The company is committed to increasing R&D investment for new products and has the capability to develop various products for different diseases based on its original blood perfusion technology [3] Group 3: Procurement and Market Strategy - In March 2024, the company participated in the inter-provincial procurement of blood dialysis medical consumables in Henan, securing qualifications for high-flow and non-high-flow blood dialysis devices, as well as blood dialysis tubing products [4] - The company has established a solid foundation for deepening its presence in the blood purification market, with a demand of approximately 900,000 units for its products from around 800 medical institutions [4] Group 4: Financial Performance and Future Outlook - The company is currently operating smoothly, with production capacity meeting business development needs and utilization rates within a reasonable range [5] - There is confidence in returning to a stable growth trajectory, with specific operational details to be disclosed in regular reports [5]